The case for non-penetrating glaucoma surgery

Article

Personal experience in a wider context

To date, raised intraocular pressure (IOP) remains the only modifiable risk factor in glaucoma management. The aim of glaucoma surgery is to lower IOP and thus curb the progression of glaucomatous optic nerve damage, especially in cases refractory to topical therapy.

While full-thickness trabeculectomy penetrates the eye, NPGS does not. With the globe remaining intact, there is a relatively controlled flow of aqueous through the TDM, thus preventing sudden intra- and postoperative hypotony. The superior safety profile of NPGS as compared with full-thickness trabeculectomy is further evidenced by a relatively low risk of blebitis and endophthalmitis.1

Even though there is an extensive literature devoted to fullthickness glaucoma surgery, sufficiently large and comparable longterm studies reporting on the efficacy and reproducibility of NPGS are pending. This is one of the main reasons why, despite its apparent advantages, NPGS is not widely performed.

Variants of NPGS

The idea of NPGS was first explored in the 1960s. Today, the basic NPGS procedure can be described as a deep sclerectomy (DS). In addition, NPGS encompasses viscocanalostomy and canalopasty, both of which aim to increase flow through Schlemm's canal.3

DS can be combined with spacemaintainer implants, the aim of which is to avoid secondary collapse of the superficial flap. The use of antimetabolites such as mitomycin C (MMC) reduces the risk of bleb scarring and, therefore, enhances the rate of success of NPGS, which, although to a lesser extent than trabeculectomy, is bleb dependent.

Operative technique

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Related Content
© 2025 MJH Life Sciences

All rights reserved.